EP3279198A1 — Crystal form of n-[6-(cis form-2,6-dimethylmorpholine-4-group)pyridine-3- group]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3- formamide monophosphate, and preparation method therefor
Assigned to Crystal Pharmatech Co Ltd · Expires 2018-02-07 · 8y expired
What this patent protects
The present disclosure relates to novel crystalline forms of N-[6-(cis -2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-methyl)-4'-(trifluoromethoxy) [1,1'-biphenyl]-3-carboxamide monophosphate, and process of preparation thereof. The crystalline form of the monophosphate of a compo…
USPTO Abstract
The present disclosure relates to novel crystalline forms of N-[6-(cis -2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-methyl)-4'-(trifluoromethoxy) [1,1'-biphenyl]-3-carboxamide monophosphate, and process of preparation thereof. The crystalline form of the monophosphate of a compound of formula (I) has low hygroscopicity, is convenient to store, has better stability than that of diphosphonate in prior art, can avoid the risk of crystal transformation in the development and production of the drug. The preparation method is simple, has low cost, and has important value for further optimization and development of the drug.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.